Female sexual dysfunction and Escitalopram antidepressant

Document Type : Original Article

Authors

1 Andrology & Dermatology Department, Faculty of Medicine, Assuit University, Egypt

2 Psychiatry Department, Faculty of Medicine, Beni-Suef University, Egypt

3 Andrology & STDs Department, Faculty of Medicine, Beni-Suef University, Egypt

4 Resident doctor of Dermatology and Andrology, Bani Mazar Hospital

Abstract

Depression is major risk factor for sexual dysfunction (SD),and vice versa. Relative to men, women are at increased risk for depression and anxiety, as well as increased risk of SD. Depression may impair sexual well-being by reducing motivation for or reward from engaging in pleasurable activities, interfering with intimate relationship, or increasing the risk  of smoking or substance abuse. SD associated with depression and SSRIs affects all phase of sexual activity, including desire, arousal, and orgasm. Escitalopram, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) group . Escitalopram is  principally used to treat major depressive disorder or generalized anxiety disorder . Escitalopram, like other SSRIs, can  provoke various types of sexual dysfunction such as anorgasmia,  decreased libido, genital numbness, and sexual anhedonia , pleasureless orgasm. Conclusion: Although escitalopram is associated with FSD , yet , females with mild to moderate depression disorder should be treated with it otherwise they will suffer from SD.

Keywords

Main Subjects

References

1- Bonierbale M., Tignol J.(2003) The ELIXIR study: Evaluation of sexual dysfunction in 4 557 depressed patients in France.
2- Laumann E, Paik A, Rosen R. (1999) Sexual dysfunction in the United States prevalence and predictors. JAMA; 281: 537–544.
3- Lorenz T,Rullo J,Faubion S(2016). Antidepressant-Induced Female Sexual Dysfunction. In Mayo Clinic Proceeding (Vol.91,No.9,pp. 1280-1286).Elsevier.
4- Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe M et al (2005).Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med;2:793–800.
5-Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB (2008).Sexual problems and distressin United States women: Prevalence and correlates. Obstet Gynecol.112(5):970-978.
6- Clayton AH, Montejo AL (2006).Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67(suppl 6):33-7.
7- Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH (2015).Effect of Vortioxetine vs. Escitalopram on Sexual Functionning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. The journal of sexual medicine 1;12(10):2036-48.
8-Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. (2007) Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med; 4 : 917–929.
9- Serretti A, Chiesa A (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol.29:259-66.
10- Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN (2011). "Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis". Annals of Internal Medicine. 155 (11): 772–85.
11- Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN (2014). Sexual dysfunction associated with second –generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf 37:19-31.
12- Atlantis, E, Sullivan, T. Bidirectional association between depression and sexual dysfunction (2012) a systematic review and meta-analysis. J Sex Med; 9: 1497–1507.
13- Clayton, AH, ElHaddad, S, Iluonakhamhe, JP.(2014) Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf; 13: 1361–1374.
14-  Baldwin, DS, Manson, C, Nowak, M.  (2015)Impact of antidepressant drugs on sexual function and satisfaction. CNS Drugs; 29: 905–913.
15- Nappi, RE, Cucinella, L.(2015). Advances in pharmacotherapy for treating female sexual dysfunction .Expert Opin- Pharmacother 216:875-887.
16-Bijlsma, EY, Chan, JSW, Olivier, B. (2014) Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav; 121: 88–101.
17- Fruhauf, S, Gerger, H, Schmidt, HM. (2003)Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav; 42: 915–933.
18-Brotto, LA, Basson, R.(2014) Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther; 57: 43–54.
19- Thorp, J, Palacios, S, Symons, J. (2014) Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG; 121: 1328–1332.
20- Gao, Z, Yang, D, Yu, L. (2015) Efficacy and safety of flibanserin in women and hypoactive sexual desire disorder: a systematic review and meta-analysis. J Sex Med; 12: 2095–2104.
21-Balon, R. (2016)Flibanserin for hypoactive sexual desire disorder in premenopausal women. Curr Psychiatry; 15: 61–64.
22- Vallejos, X, Wu, C. (2017)Flibanserin: a novel, nonhormonal agent for the treatment of hypoactive sexual desire disorder in premenopausal women. J Pharm Pract; 30: 256–260.
23- Kingsberg, SA, Woodard, T. (2015)Female sexual dysfunction: focus on low desire. Obstet Gynecol; 125: 477–486.
24- Diaz, VA, Close, JD. (2010)Male sexual dysfunction. Prim Care Clin Office Pract; 37: 473–489.
25-Schweitzer, I, Maguire, K, Ng, C. (2009)Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry; 43: 795–808.
26- Clayton, AH, Alkis, AR, Parikh, NB. (2016) Sexual dysfunction due to psychotropic medications. Psychiatr Clin North Am; 39: 427–463.
27- Pratap R.,Chokka and Jeffrey R. ,Hankey (2017) : Assessment and management of female sexual dysfunction in the context of depression. Journal of Therapeutic Advances in Psychopharmacology.2045125317720642 doi:10.1177

Files

Share

How to cite

Statistics